Altre lingue Jazz Pharmaceuticals plc

Azioni

JAZZ

IE00B4Q5ZN47

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
108,3 ^USD	-1,23%		+1,14%	-11,93%

02/04	Jazz Pharmaceuticals completa la richiesta di licenza alla FDA per il trattamento del cancro delle vie biliari	MT
02/04	Jazz Pharmaceuticals completa la richiesta di licenza biologica di Zanidatamab per il tumore delle vie biliari metastatico HER2-Positivo precedentemente trattato	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

The PharmaMar Group presents financial results for the first quarter of 2024	24/04
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024	17/04
Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	02/04
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	02/04
Jazz Pharmaceuticals : Zanidatamab R&D Day	19/03
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024	12/03
Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)	07/03
Jazz Pharmaceuticals : Corporate Overview	01/03
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016.	28/02
Jazz: Q4 Earnings Snapshot	28/02
Jazz Pharmaceuticals Swings to Q4 Non-GAAP Earnings, Revenue Rises; 2024 Guidance Set, Shares Down After Hours	28/02
(JAZZ) JAZZ PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $18.15 - $19.35	28/02
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue $4B-$4.2B	28/02
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q4 EPS $5.02, vs. Street Est of $5.18	28/02
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q4 Revenue $1.01B, vs. Street Est of $1.01B	28/02
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance	28/02
Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024	28/02
Jazz Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors	27/02
Jazz Pharmaceuticals Announces Board Changes	27/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Jazz Pharmaceuticals plc

Azioni

JAZZ

IE00B4Q5ZN47

Altre lingue

Filtri